These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33651370)

  • 1. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
    Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
    Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA.
    Yue X; Huang B; Hincapie AL; Wigle PR; Li Y; Qiu T; Lovell DJ; Morgan EM; Guo JJ
    Rheumatology (Oxford); 2021 Sep; 60(9):4063-4073. PubMed ID: 34469569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching.
    Brunelli JB; Silva CA; Pasoto SG; Saa CGS; Kozu KT; Goldenstein-Schainberg C; Leon EP; Vendramini MBG; Fontoura N; Bonfa E; Aikawa NE
    Clin Rheumatol; 2020 Feb; 39(2):515-521. PubMed ID: 31707543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?
    Polat MC; Çelikel E; Tekin ZE; Kurt T; Kaplan MM; Güngörer V; Tekgöz N; Sezer M; Karagöl C; Coşkun S; Öner N; Sezer S; Acar BÇ
    Eur J Pediatr; 2024 Jun; 183(6):2725-2731. PubMed ID: 38554171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
    Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
    Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.
    Beukelman T; Ringold S; Davis TE; DeWitt EM; Pelajo CF; Weiss PF; Kimura Y;
    J Rheumatol; 2012 Sep; 39(9):1867-74. PubMed ID: 22859354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis.
    Weiss PF; Xiao R; Brandon TG; Pagnini I; Wright TB; Beukelman T; Morgan-DeWitt E; Feudtner C
    J Rheumatol; 2018 Jan; 45(1):107-114. PubMed ID: 28916542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study.
    Tappeiner C; Klotsche J; Sengler C; Niewerth M; Liedmann I; Walscheid K; Lavric M; Foell D; Minden K; Heiligenhaus A
    Arthritis Rheumatol; 2018 Oct; 70(10):1685-1694. PubMed ID: 29732713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
    Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
    Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab or etanercept as first line biologic therapy in enthesitis related arthritis (ERA) - a drug-survival single centre study spanning 10 years.
    Shipa MR; Heyer N; Mansoor R; Deakin CT; Madenidou AV; Bouraioui A; Fisher C; Leandro M; Ciurtin C; Sen D
    Semin Arthritis Rheum; 2022 Aug; 55():152038. PubMed ID: 35660170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate.
    Alexeeva E; Dvoryakovskaya T; Denisova R; Sleptsova T; Isaeva K; Chomahidze A; Fetisova A; Mamutova A; Alshevskaya A; Gladkikh V; Moskalev A
    Pediatr Neonatol; 2019 Oct; 60(5):549-555. PubMed ID: 30885783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis.
    Klotsche J; Klein A; Niewerth M; Hoff P; Windschall D; Foeldvari I; Haas JP; Horneff G; Minden K
    Arthritis Res Ther; 2021 Apr; 23(1):118. PubMed ID: 33863349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.
    Raab A; Kallinich T; Huscher D; Foeldvari I; Weller-Heinemann F; Dressler F; Kuemmerle-Deschner JB; Klein A; Horneff G
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):41. PubMed ID: 33752685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
    Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
    Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs.
    Morozova N; Avramovič MZ; Markelj G; Toplak N; Avčin T
    Clin Rheumatol; 2024 Jul; 43(7):2287-2293. PubMed ID: 38775868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.